Summaries on a sampling of prominent recent appellate decisions in US patent cases will be presented, including:

1)  Association for Molecular Pathology v. Myriad Genetics, Inc., (Sup. Ct., 2013), providing the last word in this protracted case on the patentability of DNA.

2) Akamai Technologies, Inc. v. Limelight Networks, Inc., Nos. 2009-1372, -1380, -1416, -1417, and McKesson Technologies, Inc. v. Epic Systems Corp., No. 2010-1291 (Fed. Cir. Aug. 31, 2012) (en banc), addressing the divided infringement of method claims.

3)  Medtronic Inc. v. Boston Scientific Corp., 695 F.3d 1266 (Fed. Cir. 2012), dealing with a patent licensee's burden of proof for declaratory judgment of noninfringement.

4) Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. (Fed. Cir. 2013), concerning the indefiniteness of quantitative claim limitations.